February 10, 2025European Heart Journal - Cardiovascular Pharmacotherapy11 citationsOpen Access

Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis

YLYu‐Min LinChi Mei Medical Center JWJheng-Yan WuKaohsiung Medical University MLMei-Chuan LeeNational Cheng Kung University Hospital

Structured PICO

Do GLP-1 RAs and SGLT2is reduce MACE in patients with atherosclerotic cardiovascular disease compared to placebo or standard care?

Population

151,789 patients with atherosclerotic cardiovascular disease (ASCVD) pooled from 26 randomized controlled trials

Intervention

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose cotransporter-2 inhibitors (SGLT2is) as a class

Comparator

Placebo or standard care

Outcome

Major adverse cardiovascular events (MACE), defined as cardiovascular mortality, non-fatal myocardial infarction, and non-fatal strokecomposite

GLP-1 RAs and SGLT2is both reduce MACE in ASCVD patients, with GLP-1 RAs showing particular benefit in peripheral artery disease and post-acute events, and SGLT2is showing unique advantages in comorbid chronic kidney disease.

Abstract

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) encompasses various phenotypes with elevated risks of major adverse cardiovascular events (MACEs). This study aimed to assess the comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) across diverse ASCVD phenotypes. METHODS AND RESULTS: We conducted a systematic review and meta-analysis of randomized controlled trials evaluating GLP-1 RAs or SGLT2is against placebo or standard care in ASCVD patients. Primary outcomes included MACE, defined as cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke. Risk ratios (RRs) with 95% confidence interval (CI) were calculated using a random-effects model.Twenty-six trials (151 789 patients) were included. Both GLP-1 RAs and SGLT2is significantly reduced MACE rates in ASCVD patients (RR 0.85; 95% CI 0.80-0.91 for both). GLP-1 RAs showed significant effectiveness in peripheral artery disease (RR 0.86; 95% CI 0.76-0.98) and post-acute cardiovascular events (RR 0.90; 95% CI 0.83-0.97). In ASCVD with heart failure, both drug classes reduced MACE (GLP-1 RAs: RR 0.73; 95% CI 0.63-0.84; SGLT2is: RR 0.86; 95% CI 0.78-0.95). SGLT2is significantly reduced MACE in ASCVD with chronic kidney disease (RR 0.84; 95% CI 0.72-0.99), particularly in severe albuminuria (RR 0.61; 95% CI 0.37-0.99). CONCLUSION: GLP-1 RAs and SGLT2is exhibit distinct cardiovascular effectiveness profiles across ASCVD phenotypes. GLP-1 RAs show particular benefits in peripheral artery disease and post-acute cardiovascular events, while SGLT2is demonstrate unique advantages in ASCVD with comorbid chronic kidney disease. Both are effective in heart failure. These findings support tailored treatment strategies for diverse ASCVD participants based on specific comorbidities and risk factors.

Ask AI

Helpful

Bookmark

View Full Paper